

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the prospectus dated December 19, 2022 (the “**Prospectus**”) issued by Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or to any person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended from time to time, (the “**U.S. Securities Act**”)) (“**U.S. Persons**”) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere.

The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold (1) solely to QIBs as defined in Rule 144A pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, UBS AG Hong Kong Branch as stabilization manager (the “**Stabilization Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period on and after the Listing Date. However, there is no obligation on the Stabilization Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilization Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on January 21, 2023, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on January 21, 2023, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

In connection with the Global Offering, UBS AG Hong Kong Branch and Essence International Securities (Hong Kong) Limited together act as the Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, Joint Lead Managers and the Capital Market Intermediaries. Futu Securities International (Hong Kong) Limited, Livermore Holdings Limited and Silverbricks Securities Company Limited together act as the Joint Lead Managers and the Capital Market Intermediaries.

Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 10,694,800 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 1,069,600 H Shares
Number of International Offer Shares	: 9,625,200 H Shares (including 385,470 Reserved Shares under the Preferential Offering, subject to the Over-allotment Option)
Offer Price	: HK\$19.80 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%
Nominal Value	: RMB1.00 per H Share
Stock Code	: 6955

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*



Joint Lead Managers (in alphabetical order)



ANNOUNCEMENT OF ALLOTMENT RESULTS

SUMMARY

Net Proceeds from the Global Offering

- Based on the Offer Price of HK\$19.80 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deducting the underwriting commissions, fees and other estimated expenses paid and payable by the Company in connection with the Global Offering, assuming that the Over-allotment Option is not exercised, is estimated to be approximately HK\$152.8 million. The Company intends to apply such net proceeds in accordance with the purposes as set out in the section headed “Net Proceeds from the Global Offering” in this announcement.
- If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$29.1 million for 1,604,200 H Shares to be issued upon the exercise of the Over-allotment Option. The Company intends to apply the additional net proceeds on a pro-rata basis in accordance with the purposes as set out in the section headed “Net Proceeds from the Global Offering” in this announcement in the event that the Over-allotment Option is exercised.

Applications and Indications of Interest Received in the Hong Kong Public Offering and the Preferential Offering

- The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been moderately over-subscribed. A total of 1,869 valid applications have been received pursuant to the Hong Kong Public Offering through giving **electronic application instructions** to HKSCC via CCASS and through the **White Form eIPO** service for a total of 2,264,000 Offer Shares, representing approximately 2.12 times the total number of 1,069,600 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- The reallocation procedure as described in the section headed “Structure of the Global Offering – Hong Kong Public Offering – Reallocation” in the Prospectus has not been applied. The final number of Offer Shares allocated to the Hong Kong Public Offering is 1,069,600 Offer Shares, representing 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).
- A total of 1 valid application for Assured Entitlement and 6 valid applications for the excess Reserved Shares pursuant to the Preferential Offering from Qualifying Luye Pharma Shareholders on **BLUE** Application Forms for a total of 385,470 Reserved Shares have been received, representing approximately 0.72 times the total number of 534,800 Reserved Shares initially available under the Preferential Offering. 385,470 Reserved Shares were allocated to Qualifying Luye Pharma Shareholders. All of the unsold Reserved Shares were made available for subscription under the International Offering.

International Offering

- The Offer Shares initially offered under the International Offering have been slightly over-subscribed, representing approximately 1.52 times the total number of 9,625,200 Offer Shares initially available under the International Offering (including 385,470 Reserved Shares under the Preferential Offering and subject to the Over-allotment Option). As the number of Hong Kong Public Offer Shares validly subscribed for in the Hong Kong Public Offering represents less than 15 times the number of Hong Kong Public Offer Shares initially available for subscription under the Hong Kong Public Offering, the Overall Coordinators have decided not to exercise their authority to reallocate Offer Shares to the Hong Kong Public Offering from the International Offering and make available such reallocated Offer Shares as additional Hong Kong Public Offer Shares in accordance with guidance letter HKEX-GL91-18 issued by the Stock Exchange, and no reallocation procedure as described in “Structure and Conditions of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has taken place. The final number of International Offer Shares available under the International Offering is 9,625,200 Offer Shares, representing 90% of the total number of Offer Shares initially available under the Global Offering.
- There are a total of 220 placees under the International Offering. A total of 182 placees have been allotted two board lots of Offer Shares or less, representing approximately 83% of the total number of 220 placees under the International Offering. A total of 173 placees have been allotted one board lot of Shares, representing approximately 79% of the total number of 220 placees under the International Offering.

Cornerstone Investors

- Based on the Offer Price of HK\$19.80 per Offer Shares (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements, the Cornerstone Investors will be allocated to a total of 7,594,000 Offer Shares, representing approximately 71.01% of the Offer Shares pursuant to the Global Offering and approximately 1.49% of the H Shares in issue and the total issued share capital immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised). Please refer to the section headed “Cornerstone Investors” in the Prospectus for further details of the Cornerstone Investors.

Placing of Offer Shares with consent under paragraph 5(2) of the Placing Guidelines

- We have applied to the Stock Exchange for, and the Stock Exchange has granted us, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate Offer Shares in the Global Offering to an existing shareholder (or its close associates) of a Controlling Shareholder of the Company as a placee under the International Offering. Further details are set out in the section headed “International Offering – Placing of Offer Shares with consent under paragraph 5(2) of the Placing Guidelines” in this announcement.

Over-allotment Option

- In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Purchasers, exercisable by the Overall Coordinators (on behalf of the International Purchasers), at any time from the Listing Date to January 21, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 1,604,200 additional H Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover the over-allocations in the International Offering, if any. There has been an over-allocation of 1,604,200 Offer Shares in the International Offering. In the event the Over-allotment Option is exercised, an announcement will be made on the website of the Company at www.boan-bio.com and the website of the Stock Exchange at www.hkexnews.hk. As of the date of this announcement, the Over-allotment Option has not been exercised.

Lock-up Period Restrictions

- The Company, the Controlling Shareholders, the other existing Shareholders (including the Pre-IPO Investors) and the Cornerstone Investors are subject to certain lock-up period restrictions which are described in the section headed “Lock-up Period Restrictions” in this announcement.

Results of Allocations

- The level of applications in the Hong Kong Public Offering and Preferential Offering, the indication of level of interest in the International Offering and the basis of allocation of the Hong Kong Offer Shares and Reserved Shares, will be available on Thursday, December 29, 2022 on the website of the Company at www.boan-bio.com and the website of the Stock Exchange at www.hkexnews.hk.
- The results of allocations in the Hong Kong Public Offering and Preferential Offering (with successful applicants’ identification document numbers, where appropriate) and the number of Hong Kong Offer Shares, successfully applied for, will be made available at the times and dates and in the manner set out below:
 - (i) in the announcement to be posted on the website of the Company at www.boan-bio.com and the website of the Stock Exchange at www.hkexnews.hk by no later than 9:00 a.m. on Thursday, December 29, 2022;
 - (ii) from the designated results of allocations website at www.iporesults.com.hk (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Thursday, December 29, 2022 to 12:00 midnight on Wednesday, January 4, 2023; and
 - (iii) from the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Thursday, December 29, 2022, Friday, December 30, 2022, Tuesday, January 3, 2023 and Wednesday, January 4, 2023.

- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **White Form eIPO**” in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature. Please note that the list of identification document numbers set out in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Hong Kong Offer Shares through their brokers can consult their brokers to enquire about their application results.
- Since applications are subject to Personal Information Collection Statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **White Form eIPO**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

Despatch/Collection of H Share Certificates/e-Refund Payment Instructions/Refund Cheque(s)

- Applicants who applied for (i) 100,000 or more Hong Kong Offer Shares through **White Form eIPO** service; or (ii) **BLUE** Application Form for 100,000 or more Reserved Shares under Preferential Offering and have provided all information required by the Application Form may collect any refund cheque (where applicable) and/or H Share certificates in person from our H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong from 9:00 a.m. to 1:00 p.m. on Thursday, December 29, 2022 or such other date as notified by us as the date of dispatch/collection of H Share certificates/e-Refund payment instructions/refund cheque.
- Applicants being individuals who are eligible for personal collection cannot authorize any other person to make collection on their behalf. Corporate applicants which are eligible for personal collection must attend by their authorized representatives bearing letters of authorization from their corporations stamped with the corporations’ chops. Both individuals and authorized representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Computershare Hong Kong Investor Services Limited.

- H Share certificates for Hong Kong Offer Shares allotted to applicants who applied for less than 100,000 Hong Kong Offer Shares through the **White Form eIPO** are expected to be despatched to those entitled to the addresses specified in the relevant application instructions by ordinary post at their own risk on or before Thursday, December 29, 2022.
- H Share certificates and/or refund cheque(s) for Hong Kong Offer Shares allocated to applicants who applied through the **White Form eIPO** service which are either not available for personal collection or which are available but are not collected in person by 1:00 p.m. on Thursday, December 29, 2022 are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on or before Thursday, December 29, 2022.
- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their H Share certificates issued in the name of HKSCC Nominees Limited and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave **electronic application instructions** on their behalf on Thursday, December 29, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies payable to them with that CCASS Participant.
- Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS should check and report any discrepancies to HKSCC before 5:00 p.m. on Thursday, December 29, 2022 or such other date as shall be determined by HKSCC or HKSCC Nominees. Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS may also check the results of their applications and the amount of refund monies payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time). Immediately following the credit of the Hong Kong Offer Shares to the CCASS Investor Participants stock accounts and the credit of the refund monies to their respective designated bank account (if any), HKSCC will also make available to the CCASS Investor Participants an activity statement showing the number of the Hong Kong Offer Shares credited to their stock accounts and the amount of refund monies (if any) credited to their respective designated bank accounts.

- Applicants who applied through the **White Form eIPO** service and paid the application monies from a single bank account may have refund monies (if any) despatched to their application payment account in the form of e-Refund payment instructions on Thursday, December 29, 2022. Applicants who applied through the **White Form eIPO** service and paid the application monies from multiple bank accounts will have refund monies (if any) despatched to the addresses specified on their **White Form eIPO** applications in the form of refund cheque(s) in favour of the applicant (or, in case of joint applications, the first-named applicant), by ordinary post at their own risk on or before Thursday, December 29, 2022.
- Refund monies for applicants who have applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to their designated bank accounts or the designated bank accounts of their **brokers** or **custodians** on Thursday, December 29, 2022.
- H Share certificates will only become valid at 8:00 a.m. (Hong Kong time) on Friday, December 30, 2022 provided that the Global Offering has become unconditional in all respects at or before that time and neither of the Hong Kong Underwriting Agreement nor the International Purchase Agreement is terminated in accordance with its respective terms prior to 8:00 a.m. on Friday, December 30, 2022.
- The Company will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

Public Float

- The Company confirms that immediately after the completion of the Global Offering, 92,400,182 H Shares, representing approximately 18.14% of the total issued Shares upon completion of the Global Offering (assuming the Over-allotment Option is not exercised) will count towards the public float for the purpose of Rule 8.08 of the Listing Rules.
- The Company has applied to the Stock Exchange to request the Stock Exchange to exercise its discretion under Rule 8.08(1)(d) of the Listing Rules, and the Stock Exchange has granted a waiver from strict compliance with the requirements of Rule 8.08(1)(a) of the Listing Rules, pursuant to which the public float of the Company may fall below 25% of the issued share capital (assuming the Over-allotment Option is not exercised) or such higher percentage of H Shares held by the public (if the Over-allotment Option is fully or partially exercised).

- The Directors confirm that (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company immediately after the Global Offering; (iii) the number of Shares in public hands will satisfy the minimum percentage as approved by the Stock Exchange; (iv) the three largest public Shareholders of the Company do not hold more than 50% of the Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (v) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.
- Immediately following completion of the Global Offering and before the exercise of the Over-allotment Option, (i) the number of H Shares in public hands will be 92,400,182 H Shares, representing 18.14% of the total issued share capital of the Company which satisfies the minimum percentage prescribed in the conditions imposed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1) of the Listing Rules; and (ii) the Company will comply with Rule 18A.07 of the Listing Rules that a portion of the total number of the Company's issued shares with a market capitalization of at least HK\$375 million will be held by the public at the time of Listing.

Commencement of Dealings in the H Shares

- Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. (Hong Kong time) on Friday, December 30, 2022, dealings in the H Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. (Hong Kong time) on Friday, December 30, 2022. H Shares will be traded in board lots of 200 H Shares each. The stock code of the H Shares is 6955.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded, and should exercise extreme caution when dealing in H Shares.

NET PROCEEDS FROM THE GLOBAL OFFERING

The net proceeds from the Global Offering to be received by the Company, after deducting the underwriting commissions and other estimated expenses paid and payable by the Company in connection with the Global Offering, assuming that the Over-allotment Option is not exercised, are estimated to be approximately HK\$152.8 million.

The Company intends to apply such net proceeds in the following manner:

- (1) approximately 59.5%, or HK\$91.0 million, will be used for the research and development of the Company's Core Products;
- (2) approximately 31.4%, or HK\$48.0 million, will be used for the research and development of other products in the Company's pipeline;

- (3) approximately 6.1%, or HK\$9.3 million, will be used for commercialization purposes; and
- (4) approximately 3.0%, or HK\$4.6 million, will be used for working capital and other general corporate purposes.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$29.1 million for 1,604,200 Offer Shares to be issued upon the exercise of the Over-allotment Option.

For further information, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED IN THE HONG KONG PUBLIC OFFERING AND THE PREFERENTIAL OFFERING

The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been moderately over-subscribed. At the close of the application lists at 12:00 noon on Thursday, December 22, 2022, a total of 1,869 valid applications have been received pursuant to the Hong Kong Public Offering through the service and through giving **electronic application instructions** via CCASS for a total of 2,264,000 Offer Shares, representing approximately 2.12 times the total number of 1,069,600 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 1,868 valid applications in respect of a total of 1,964,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$19.80 per Hong Kong Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) of HK\$5 million or less, representing approximately 3.67 times the 534,800 Hong Kong Offer Shares initially comprised in pool A; and
- 1 valid application in respect of a total of 300,000 Hong Kong Offer Shares was for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$19.80 per Hong Kong Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.005%) of more than HK\$5 million, representing approximately 0.56 times the 534,800 Hong Kong Offer Shares initially comprised in pool B.

No application has been rejected due to invalid application. No multiple or suspected multiple application was identified and rejected. No dishonored payment has been identified and rejected. No application for more than 534,800 Hong Kong Offer Shares (being 50% of the 1,069,600 Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

The reallocation procedures as described in the section headed “Structure of the Global Offering – Hong Kong Public Offering – Reallocation” in the Prospectus has not been applied. The final number of Offer Shares allocated to the Hong Kong Public Offering is 1,069,600 Offer Shares, representing 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the section headed “Basis of allocation under the Hong Kong Public Offering” below.

Preferential Offering

At the close of the application lists at 12:00 noon on Thursday, December 22, 2022, a total of 1 valid application for Assured Entitlement and 6 valid applications for the excess Reserved Shares pursuant to the Preferential Offering from Qualifying Luye Pharma Shareholders on **BLUE** Application Forms for a total of 385,470 Reserved Shares have been received, representing approximately 0.72 times the total number of 534,800 Reserved Shares initially available under the Preferential Offering. None of the applications have been rejected due to invalid applications. No multiple applications or suspected multiple applications have been identified. No application has been rejected due to bounced cheque.

The final number of Reserved Shares allocated to the Preferential Offering is 385,470 Reserved Shares, representing approximately 3.60% of the Offer Shares initially available under the Global Offering (assuming no exercise of the Over-allotment Option). All of the unsold Reserved Shares were made available for subscription under the International Offering.

The Reserved Shares offered in the Preferential Offering were conditionally allocated on the basis set out in the section headed “Basis of allocation under the Preferential Offering” below.

INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering were slightly over-subscribed, representing approximately 1.52 times the total number of 9,625,200 Offer Shares initially available under the International Offering (including 385,470 Reserved Shares under the Preferential Offering, and subject to the Over-allotment Option). As the number of Hong Kong Public Offer Shares validly subscribed for in the Hong Kong Public Offering represents less than 15 times the number of Hong Kong Public Offer Shares initially available for subscription under the Hong Kong Public Offering, the Overall Coordinators have decided not to exercise their authority to reallocate Offer Shares to the Hong Kong Public Offering from the International Offering and make available such reallocated Offer Shares as additional Hong Kong Public Offer Shares in accordance with guidance letter HKEX-GL91-18 issued by the Stock Exchange, and no reallocation procedure as described in “Structure and Conditions of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has taken place. The final number of International Offer Shares available under the International Offering is 9,625,200 Offer Shares, representing 90% of the total number of Offer Shares initially available under the Global Offering.

There are a total of 220 placees under the International Offering. A total of 182 placees have been allotted two board lots of Offer Shares or less, representing approximately 83% of the total number of 220 placees under the International Offering. A total of 173 placees have been allotted one board lot of Shares, representing approximately 79% of the total number of 220 placees under the International Offering.

Cornerstone Investors

Cornerstone Investor	Number of Offer Shares subscribed for	Approximate % of the Offer Shares initially available under the Global Offering ⁽¹⁾	Approximate % of the total issued share capital of the Company immediately following the completion of the Global Offering ⁽¹⁾
Mr. Fu	1,167,600	10.92%	0.23%
Harvest	5,050,400	47.22%	0.99%
Sino Biopharm	1,376,000	12.87%	0.27%
Total	7,594,000	71.01%	1.49%

Note:

(1) Assuming that the Over-allotment Option is not exercised.

Based on the Offer Price of HK\$19.80 per Offer Shares (exclusive of brokerage of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements, the Cornerstone Investors will be allocated with a total of 7,594,000 Offer Shares, representing approximately 71.01% of the Offer Shares pursuant to the Global Offering and approximately 1.49% of the H Shares in issue and the total issued share capital immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised). Please refer to the section headed “Cornerstone Investors” in the Prospectus for further details of the Cornerstone Investors.

To the best knowledge of the Directors after making reasonable enquiries, (i) each of the Cornerstone Investors is an Independent Third Party; (ii) none of the Cornerstone Investors is accustomed to take instructions from the Company, its subsidiaries, the Directors, the Supervisors, chief executive of the Company, the Controlling Shareholders, substantial Shareholders, the existing Shareholders or their respective close associates in relation to the acquisition, disposal, voting, or other disposition of the Offer Shares registered in his/its name or otherwise held by him/it; and (iii) none of the subscription of the relevant Offer Shares by any of the Cornerstone Investors is, directly or indirectly, financed by the Company, the Directors, the Supervisors, chief executive of the Company, the Controlling Shareholders, substantial Shareholders, the existing Shareholders or any of their subsidiaries or their respective close associates. There are no side arrangements or agreements between the Company and the Cornerstone Investors by virtue of or in relation to the Cornerstone Placing, other than a guaranteed allocation of the relevant Offer Shares at the Offer Price.

As confirmed by each of the Cornerstone Investors, their subscription under the Cornerstone Placing would be financed by their own financial resources. Each of the Cornerstone Investors has confirmed that all necessary approvals have been obtained with respect to the Cornerstone Placing and that no specific approval from any stock exchange (if relevant) or its shareholders (if relevant) is required for the relevant cornerstone investment as each of them has general authority to invest. There will not be deferred settlement in payment and each of the Cornerstone Investors will pay in full for their subscription under the Cornerstone Placing.

Each of the Cornerstone Investors has, where applicable, agreed that without the prior written consent of each of the Company, the Joint Sponsors and the Joint Global Coordinators, he/it will not, whether directly or indirectly, at any time during the period of six months from the Listing Date (the “**Lock-up Period**”), (i) dispose of, in any way, any of the Offer Shares he/it has purchased pursuant to the relevant Cornerstone Investment Agreement or any interest in any company or entity holding any of such Offer Shares; (ii) allow itself to undergo a change of control (as defined in Takeovers Code); (iii) agree or contract to, or publicly announce any intention to enter into a transaction with a third party for disposal of such Offer Shares; or (iv) enter into any transactions directly or indirectly with the same economic effect as any aforesaid transaction, save for certain limited circumstances, such as transfers to any of his/its wholly-owned subsidiaries which will be bound by the same obligations of such Cornerstone Investors, including the Lock-up Period restriction.

Please refer to the section headed “Cornerstone Investors” in the Prospectus for further details relating to the Cornerstone Investors.

Confirmations of Public Shareholders in the Hong Kong Public Offering and Placees in the International Offering

The Directors confirm that, to the best of their knowledge, information and belief, save as disclosed in the below section “– Placing of Offer Shares with consent under paragraph 5(2) of the Placing Guidelines”, (i) each of the public Shareholders in the Hong Kong Public Offering and placees in the International Offering is an Independent Third Party and is not a connected person (as defined under the Listing Rules) of the Company; (ii) none of the Offer Shares subscribed by public Shareholders in the Hong Kong Public Offering and placees in the International Offering has been directly or indirectly financed by the Company, the Directors, the Supervisors, chief executive, the Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of their subsidiaries or their respective close associates; (iii) none of the public Shareholders in the Hong Kong Public Offering and placees in the International Offering who has subscribed for the Offer Shares is accustomed to taking instructions from the Company, the Directors, the Supervisors, chief executive, the Controlling Shareholders, substantial Shareholders of the Company or any of their subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their name or otherwise held by them and (iv) there is no side agreement or arrangement between the Company, any of the Directors, the Supervisors, chief executive, the Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of their subsidiaries or their respective close associates, on one hand, and the public Shareholders or the placees who have subscribed for the Offer Shares, on the other hand.

Placings of Offer Shares with consent under paragraph 5(2) of the Placing Guidelines

A total of 4,000 H Shares, representing approximately 0.0374% and 0.000785% of the total Offer Shares available under the Global Offering (assuming the Over-allotment Option is not exercised) and the total number of H Shares in issue immediately following completion of the Global Offering, respectively, were placed to TruMed Healthcare Master Fund. TruMed Healthcare Master Fund is an existing shareholder of Luye Pharma, holding approximately 0.008% of the issued share capital of Luye Pharma as at the date of this announcement. Luye Pharma is a Controlling Shareholder of the Company. The Stock Exchange has given its consent for the placing of such Offer Shares to TruMed Healthcare Master Fund under paragraph 5(2) of the Placing Guidelines.

Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Purchasers, exercisable by the Overall Coordinators (for themselves and on behalf of the International Purchasers), at any time from the Listing Date to January 21, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 1,604,200 additional Offer Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the same price per Offer Price under the International Offering to cover the over-allocations in the International Offering, if any. There has been an over-allocation of 1,604,200 Offer Shares in the International Offering and such over-allocation will be settled using the H Shares purchased by the Stabilization Manager (or any person acting for it) in the secondary market, exercising the Over-allotment Option in part or through delayed delivery arrangements with investors who have been allocated Offer Shares in the International Offering and have agreed to such delayed delivery arrangements. There will not be any deferred settlement in payment and the investors under the delayed delivery arrangements will fully pay for their Offer Shares before dealings in the H Shares on the Stock Exchange commence. In the event the Over-allotment Option is exercised, an announcement will be made on the website of the Company at www.boan-bio.com and the website of the Stock Exchange at www.hkexnews.hk. As of the date of this announcement, the Over-allotment Option has not been exercised.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the paragraph headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus, 1,869 valid applications made by the public through giving **electronic application instructions** to HKSCC via CCASS and through the **White Form eIPO** service will be conditionally allocated on the basis set out below:

No. of Shares applied for	No. of valid applications	Basis of allotment/ballot	Approximate percentage allotted of the total no. of Shares Applied for
POOL A			
200	1,266	555 out of 1,266 to receive 200 Shares	43.84%
400	233	204 out of 233 to receive 200 Shares	43.78%
600	52	200 Shares plus 16 out of 52 to receive additional 200 Shares	43.59%
800	30	200 Shares plus 22 out of 30 to receive additional 200 Shares	43.33%
1,000	57	400 Shares plus 9 out of 57 to receive additional 200 Shares	43.16%
1,200	12	400 Shares plus 7 out of 12 to receive additional 200 Shares	43.06%
1,400	15	600 Shares	42.86%
1,600	8	600 Shares plus 3 out of 8 to receive additional 200 Shares	42.19%
1,800	9	600 Shares plus 6 out of 9 to receive additional 200 Shares	40.74%
2,000	72	800 Shares plus 5 out of 72 to receive additional 200 Shares	40.69%

No. of Shares applied for	No. of valid applications	Basis of allotment/ballot	Approximate percentage allotted of the total no. of Shares Applied for
3,000	17	1,200 Shares plus 1 out of 17 to receive additional 200 Shares	40.39%
4,000	10	1,600 Shares	40.00%
5,000	22	2,000 Shares	40.00%
6,000	8	2,400 Shares	40.00%
7,000	3	2,800 Shares	40.00%
8,000	1	3,200 Shares	40.00%
9,000	1	3,600 Shares	40.00%
10,000	43	3,800 Shares	38.00%
20,000	2	7,600 Shares	38.00%
30,000	1	11,200 Shares	37.33%
40,000	2	14,800 Shares	37.00%
50,000	2	18,000 Shares	36.00%
80,000	1	27,400 Shares	34.25%
250,000	1	85,600 Shares	34.24%
	<u>1,868</u>	Total number of Pool A successful applicants: 1,128	
		POOL B	
300,000	<u>1</u>	300,000 Shares	100.00%
	<u>1</u>	Total number of Pool B successful applicants: 1	

The final number of Offer Shares comprising the Hong Kong Public Offering is 1,069,600 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (assuming the Over-allotment Option is not exercised).

BASIS OF ALLOCATION UNDER THE PREFERENTIAL OFFERING

The final number of Reserved Shares allocated to Qualifying Luye Pharma Shareholders in the Preferential Offering is 385,470 Reserved Shares, representing approximately 3.6% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). Such 385,470 Reserved Shares have been allocated to a total of 7 Qualifying Luye Pharma Shareholders. Among the Reserved Shares allocated, 1 valid application in respect of a total of 200,497 Reserved Shares will be allocated to Qualifying Luye Pharma Shareholders as their Assured Entitlement and 6 valid applications in respect of a total of 184,973 Reserved Shares will be allocated to Qualifying Luye Pharma Shareholders under their valid applications for excess Reserved Shares.

No preferential treatment was given to any of the Qualifying Luye Pharma Shareholders in the allocation of the Reserved Shares applied for by them under the Preferential Offering and such allocation of Reserved Shares under the Preferential Offering was made in accordance with the allocation basis disclosed in the section headed “Structure of the Global Offering – The Preferential Offering – Basis of allocation for applications for Reserved Shares” in the Prospectus. Valid applications made by Qualifying Luye Pharma Shareholders for excess Reserved Shares on **BLUE** Application Forms will be conditionally allotted on the basis set out below:

Preferential Offering

					Approximate percentage of allocation based on the total number of Excess Reserved Shares applied for in this category
Number of Excess Reserved Shares applied for	Number of Valid Excess Applications	Total number of Excess Reserved Shares applied for	Basis of allotment	Total number of Reserved Shares allotted	
3 to 5	5	23	Allot Excess Reserved Shares applied for in full	23	100.00%
184,950	1	184,950	Approximately 100.00% of the Excess Reserved Shares applied for (HKSCC Nominees Limited apply on behalf of the applicants who apply in CCASS indirectly through a broker/custodian)	184,950	100.00%
Total	6	184,973		184,973	

Out of the 1 valid application for Assured Entitlement and 6 valid applications for the excess Reserved Shares received pursuant to the Preferential Offering as at 12:00 noon on Thursday, December 22, 2022, all such valid applications for a total of 385,470 Reserved Shares have been validly confirmed by the Qualifying Luye Pharma Shareholders, representing (i) approximately 72.08% of the total number of 534,800 Reserved Shares initially available under the Preferential Offering; and (ii) representing approximately 3.60% of the Offer Shares initially available under the Global Offering (assuming no exercise of the Over-allotment Option). 149,330 un-subscribed Reserved Shares have been reallocated to the International Offering.

LOCK-UP PERIOD RESTRICTIONS

The Company, the Controlling Shareholders, all the other existing Shareholders (including the Pre-IPO Investors) and the Cornerstone Investors have provided lock-up undertakings and/or are subject to Lock-up Period restrictions (the “**Lock-up Period Restrictions**”) in respect of our Shares. The major terms of the Lock-up Period Restrictions are set out as follows:

Name	Number of Shares subject to the Lock-up Period Restrictions after Listing	Percentage of shareholding in the Company subject to the Lock-up Period Restrictions after Listing ⁽¹⁾	Last day of the Lock-up Period
The Company (<i>subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement</i>)	N/A	N/A	June 30, 2023 ⁽²⁾
Controlling Shareholders			
Luye Pharma ⁽⁴⁾	360,596,456	70.81%	December 30, 2023 ⁽³⁾
AsiaPharm ⁽⁴⁾	360,596,456	70.81%	December 30, 2023 ⁽³⁾
Luye HK ⁽⁴⁾	360,596,456	70.81%	December 30, 2023 ⁽³⁾
Yantai Luye ⁽⁴⁾	360,596,456	70.81%	December 30, 2023 ⁽³⁾
Shandong Luye ⁽⁴⁾	360,596,456	70.81%	December 30, 2023 ⁽³⁾
Other existing Shareholders (<i>subject to lock-up obligations pursuant to the PRC Company Law</i>)	138,005,422	27.1%	December 30, 2023 ⁽⁵⁾
Cornerstone Investors (<i>subject to lock-up obligations pursuant to the Cornerstone Investment Agreements</i>)			
Mr. Fu	1,167,600	0.23%	June 30, 2023 ⁽⁶⁾
Harvest	5,050,400	0.99%	June 30, 2023 ⁽⁶⁾
Sino Biopharm	1,376,000	0.27%	June 30, 2023 ⁽⁶⁾

Notes:

- (1) Assuming the Over-allotment Option is not exercised.
- (2) The Company may not issue Shares prior to the indicated date except otherwise permitted by the Listing Rules.
- (3) The Controlling Shareholders may dispose of or transfer Shares without any lock-up obligation after the indicated date.
- (4) Shandong Luye is wholly owned by Yantai Luye, which in turn is wholly owned by Luye HK. Luye HK is in turn wholly owned by AsiaPharm and AsiaPharm is wholly owned by Luye Pharma.
- (5) The other existing Shareholders may dispose of or transfer Shares without any lock-up obligation after the indicated date.
- (6) Each of the Cornerstone Investors may dispose of any of the Offer Shares subscribed in the Global Offering after the indicated date.

RESULTS OF ALLOCATIONS

The level of applications in the Hong Kong Public Offering and Preferential Offering, the indication of level of interest in the International Offering and the basis of allocation of the Hong Kong Offer Shares and Reserved Shares, will be available on Thursday, December 29, 2022 on the website of the Company at [**www.boan-bio.com**](http://www.boan-bio.com) and the website of the Stock Exchange at [**www.hkexnews.hk**](http://www.hkexnews.hk).

The results of allocations in the Hong Kong Public Offering and Preferential Offering (with successful applicants' identification document numbers, where appropriate) and the number of Hong Kong Offer Shares, successfully applied for, will be made available at the times and dates and in the manner specified below:

- in the announcement to be posted on the website of the Company at [**www.boan-bio.com**](http://www.boan-bio.com) and the website of the Stock Exchange at [**www.hkexnews.hk**](http://www.hkexnews.hk) by no later than 9:00 a.m. on Thursday, December 29, 2022;
- from the designated results of allocations website at [**www.iporesults.com.hk**](http://www.iporesults.com.hk) (alternatively: English [**https://www.eipo.com.hk/en/Allotment**](https://www.eipo.com.hk/en/Allotment); Chinese [**https://www.eipo.com.hk/zh-hk/Allotment**](https://www.eipo.com.hk/zh-hk/Allotment)) with a “search by ID” function from 8:00 a.m. on Thursday, December 29, 2022 to 12:00 midnight on Wednesday, January 4, 2023; and
- from the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Thursday, December 29, 2022, Friday, December 30, 2022, Tuesday, January 3, 2023 and Wednesday, January 4, 2023.

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **White Form eIPO**” in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature. Please note that the list of identification document numbers set out in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Hong Kong Offer Shares through their brokers can consult their brokers to enquire about their application results.

Since applications are subject to Personal Information Collection Statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **White Form eIPO**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

SHAREHOLDING CONCENTRATION ANALYSIS

Set out below is an analysis of shareholding concentration in the Global Offering.

- subscription and number of Shares held by the top 1, 5, 10 and 25 of the placees out of the International Offer Shares, total Offer Shares and the total issued share capital of the Company upon Listing:

Placees	Subscription	H Shares held following the Global Offering	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
Top 1	5,050,400	5,050,400	54.66%	46.57%	47.22%	41.06%	0.99%	0.99%
Top 5	10,739,800	10,739,800	116.23%	99.04%	100.42%	87.32%	2.11%	2.10%
Top 10	10,767,800	10,767,800	116.54%	99.30%	100.68%	87.55%	2.11%	2.11%
Top 20	10,789,000	10,789,000	116.77%	99.49%	100.88%	87.72%	2.12%	2.11%
Top 25	10,795,000	10,795,000	116.83%	99.55%	100.94%	87.77%	2.12%	2.11%

- subscription and number of Shares held by the top 1, 5, 10 and 25 of the Shareholders out of the International Offer Shares, total Offer Shares and the total issued share capital of the Company upon Listing:

Shareholder	Subscription	H Shares held following the Global Offering	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
Top 1	0	360,596,456	0.00%	0.00%	0.00%	0.00%	70.81%	70.58%
Top 5	0	422,092,556	0.00%	0.00%	0.00%	0.00%	82.88%	82.62%
Top 10	0	458,392,418	0.00%	0.00%	0.00%	0.00%	90.01%	89.73%
Top 20	8,188,200	498,740,067	88.62%	75.51%	76.56%	66.58%	97.93%	97.62%
Top 25	10,731,800	506,157,962	116.15%	98.97%	100.35%	87.26%	99.39%	99.08%

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in Shares.

Note: Beneficiary Owner Identification Code(s) are codes provided by nominees as an agent making the application for the benefit of another person in WHITE Applications Form or brokers via CCASS.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed "Results of Applications Made by WHITE Applications Forms or White Form eIPO" and "Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS" are redacted and not all details of applications are disclosed in this announcement.

The list of identification document number(s) in this announcement is not a complete list of successful applicants since only successful applicants whose identification document numbers are provided by CCASS are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated above. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result.

Identification document numbers shown in the sections headed "Results of Applications Made by WHITE Applications Forms or White Form eIPO", "Results of Applications Made by BLUE Application Forms" and "Results of Applications Made by YELLOW Application Forms (Through Designated CCASS Clearing/Custodian Participants)" refer to Hong Kong identity card numbers / passport numbers /Hong Kong business registration numbers/ beneficial owner identification codes provided by nominees as an agent making the application for the benefit of another person whereas those displayed in the section headed "Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS" are provided by brokers via CCASS. Therefore, some of the identification document numbers shown in these sections are different in nature.

附註：實益擁有人識別碼乃由經紀透過中央結算系統或由代理為其他人士利益於白色申請表格內提出申請所提供的識別碼。

由於申請須遵守個人資料收集聲明，「以白色申請表格或白表eIPO提出申請的配發結果」及「透過中央結算系統向香港結算發出電子認購指示提出申請的配發結果」等節所示的實益擁有人識別碼乃予以編纂，且並未於本公告中披露所有申請詳情。

由於僅披露由中央結算系統提供其身份證明文件號碼的獲接納申請人，故本公告中的身份證明文件號碼清單並非獲接納申請人的完整清單。僅擁有實益姓名但無身份證明文件號碼的申請人因下文所述的個人私隱而不予披露。透過彼等經紀申請認購發售股份的申請人可諮詢經紀查詢彼等的申請結果。

「以白色申請表格或白表eIPO提出申請的配發結果」、「以藍色申請表格提出申請的配發結果」及「以黃色申請表格提出申請的配發結果（透過指定中央結算系統結算／託管商參與者）」等節所示的身份證明文件號碼指香港身份證號碼、護照號碼、香港商業登記號碼、由代理為其他人士利益提出申請所提供的實益擁有人識別碼，而「透過中央結算系統向香港結算發出電子認購指示提出申請的配發結果」一節所示的該等號碼乃由經紀透過中央結算系統提供。因此，該等節所示的個別身份證明文件號碼在本質上有所不同。

The followings are the Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) (where supplied) of wholly or partially successful applicants made by giving Electronic Application Instructions to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部份獲接納的申請人的身份證明文件號碼/實益擁有人識別碼(附註)(如有提供),及彼等擁有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼/實益擁有人識別碼(附註),其結果將不會顯示。

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) 身份證明文件號碼/實益擁有人識別碼(附註)	No. of Shares allotted
0000176-00****76****00****01	200
001081719-68****26**	200
001097000-68****28**	200
002074979-68****28**	600
002102012-10****76***61	2000
002140043-68****71**	200
002194212-10****02***78	800
003105457-68****48**	400
003161013-10****26***32	1200
003183914-10****72***31	200
004040556-10****77***95	400
004220022-10****28***13	600
005212418-P1****19***AN****NG***U	200
005266512-10****28***55	200
005266968-10****69***00	200
006154817-68****43**	200
006294817-10****24***42	200
007031913-10****36***1	1600
007160464-P1****14***IU****CU*	200
007217317-10****22***5	200
008290032-18****00**	200
009046034-68****76**	200
010022469-68****60**	400
010124422-68****11**	200
010255012-10****16***10	200
01030530-69****76*	600
010725104-65****71**	200
011011619-68****39**	400
011060025-10****81***65	200
011154028-10****73***16	200
01204681X-P1****81***AN****AN*	400
01217163X-10****91***58	200
01221211-60****69*	200
012281647-10****28***93	200
01302412-61****20*	200
03100619-65****69*	200
03153629-62****65*	200
0320602X-68****73*	800
03264126-69****05*	200
03310039-63****56*	200
03314110-63****81*	600
04272836-62****65*	200
05018119-60****71*	400
05301521-66****80*	200
06053411-62****00*	200
06154817-69****17*	200
06207794-62****91*	200
06284933-61****88*	200
07140032-68****01*	200
07265331-66****79*	200
08050062-68****36*	800
08110018-67****68*	200
08151514-60****85*	200
08256622-63****60*	200
08301614-67****99*	200
09041011-65****96*	200
0909461X-62****07*	200
09183658-61****92*	200
09250021-66****02*	200
09270020-60****29*	200
0C5409320-10****93***13	27400
0D1180232-10****06***5	600
0D121160A-10****21***40	200
0D1579461-10****24***13	600
0F1718653-10****54***55	200
0G3274275-10****83***52	200
0G3582190-10****37***42	200
0G359000A-10****84***93	200
0G5207192-10****21***91	200
0HG060455-10****03***0	200
0K0600032-10****13***22	200
0K3311309-10****87***1	800
0K5601568-10****81***31	200
0K5982847-10****22***	200
0K6282814-10****55***26	200
0K7084056-10****24***29	200
0K964198A-10****38***43	200
0M0098421-10****18***11	800
0M0848854-10****27***09	200
0M1768129-10****95***89	400
0M2717994-10****27***76	600
0M8972325-10****46***48	400
0P2186873-10****21***03	200
0P6902190-10****44***70	200
0P7268304-10****16***39	200
0P7455007-10****24***23	200
0P9634731-10****33***12	800
0R0466262-10****20***82	200
0R112375A-10****85***57	200
0R1187863-10****21***90	600
0R1604766-10****33***47	200
0R2206924-10****12***29	200
0R396056A-10****75***09	2400
0R4332589-10****57***29	200
0R6488896-10****85***66	400
0R7022394-10****60***62	800
0R7288599-10****47***75	800
0R8490243-10****29***10	200
0R8721806-10****60***27	400
0R904378A-10****88***56	200
0R9385990-10****02***80	800
0V071772A-10****27***71	200
0V1369377-10****21***1	3800
0Y3408467-10****93***6	200
0Y5258462-10****82***52	600
0Z1933214-10****31***36	200
0Z2393833-10****13***19	200
0Z4143192-10****28***95	200
0Z7480696-10****89***1	200
10080663-60****08*	200
101071974-20****05***06****56	400
101233510-68****74**	400
1013251X-66****08*	200
10151391-62****13*	200
10176024-68****17*	400
10206611-69****97**	200
102210154-10****38***	2000
103012012-P1****17***HO****XU***U	200
10302002X-10****61***66	200
10305084-CA****05***	200
103133572-10****39***22	800
103261517-68****97**	800
104052538-10****35***50	200
104076836-P1****02***OU****CH***	200
104150611-68****65**	200
104153059-68****88**	600
105012010-10****99***71	400
105162825-68****10**	200
106250932-10****28***78	200
108015529-68****44**	200
108206951-10****63***23	1600
109069032-68****93**	200
109116833-P1****00***OU****OZ***G	200
109226729-68****13**	200
109244993-10****07***49	400
110011056-10****73***28	400
11010819-CM****05***4	200
11022017-63****68*	400

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) 身份證明文件號碼/實益擁有人識別碼(附註)	No. of Shares allotted
110262116-10****28***09	200
111271513-10****15***35	200
11143994-60****57*	600
112060407-10****83***00	200
112097417-10****87***39	200
112100923-68****05**	200
112124714-68****72**	200
11216611-60****15*	200
112241933-10****89***27	200
11231922-60****57*	200
1123253HH-21****49***16***7	3600
11260717-62****11*	200
12010017-69****62*	200
12010119-M5****92	200
12010319-M5****48	200
12010419-M5****31	200
12124749-66****97*	200
12244316-69****99*	200
12296515-65****99*	200
12310058-69****11*	200
128606-M8******	200
13053219-P3****02	200
13062419-P3****39	200
13070219-M5****26	200
13090319-M5****87	200
13090319-M5****87	200
1758633HH-21****22***24****9	200
1885330HH-21****44***26***5	200
1951665HH-21****15***27***8	200
20005383-38****5	200
20085951-38****1	200
201010392-68******	600
201215015-10****21***82	200
201271014-10****60***82	200
202032537-10****15***68	400
203091929-68****77**	200
204032888-10****59***97	200
204102974-20****29***85***F ***E0****00***08	200
204261649-10****50***75	200
205102613-10****59***3	1600
20519252X-68****62**	200
20721261X-P1****94***AN***O	200
208241278-10****79***71	200
208312856-68****55**	400
209201061-P1****61***IA****EN***N	3600
209231021-10****29***	400
20928095X-P1****06***IN***BE*	200
210020327-10****72***06	200
210061010-68****14**	3800
21010219-M5****80	200
21010219-M5****81	200
21010419-M3****02	200
21010419-M3****21	200
21010619-M5****45	200
21011219-M5****20	200
210137211-68****87**	200
211022017-10****61***38	200
211072512-68****65**	200
211163973-68****52**	200
211211645-68****67**	400
212060035-68****17**	400
212073076-10****25***5	400
2178216HH-21****34***31***6	400
220281197-C0****61**	200
22050219-P3****93	200
2211395HH-21****09***32***9	200
2215731HH-21****41***32***7	200
2217190HH-21****04***33***0	200
2220737HH-21****05***33***7	200
23010319-M5****01	200
23010319-M5****02	200
230252967-23****29***85***F ***E0****00***17	800
23042119-P5****04	200
23233119-M5****96	200
2356211HH-21****74***36***3	1200
2395912HH-21****47***38***2	200
264488917-26****89***85***F ***E0****00***66	1000
264582404-26****24***85***F ***E0****00***55	200
2766263HH-21****01***45***0	200
2836355HH-21****36***82***9	200
296272750-29****27***85***F ***E0****00***24	200
297866626-29****66***85***F ***E0****00***12	200
301063297-10****60***05	200
301151312-68****82**	200
30204296X-10****61***63	200
303024436-60****-8***1-*	400
303065821-10****25***40	400
303230039-10****12***15	600
303252437-10****22***60	200
303278453-60****-8***8-*	2800
304041013-10****81***83	200
305090772-68****94**	200
305124445-P1****03***AN***IQ**	200
306110215-11****50*** X***GR***	18000
306160018-10****73***11	3200
3063090HH-21****39***55***5	200
3067767HH-21****18***55***8	200
307030014-10****87***90	200
307146525-10****81***10	200
3080871HH-21****46***55***6	200
3086209HH-21****54***56***6	200
309035522-10****95***70	200
309043225-10****98***43	200
309232644-P1****87***AN***HA***ON*	200
309280415-68****65**	400
31010119-M3****76	200
31010219-M5****40	200
31010419-M5****62	200
31010419-P5****39	200
31010619-M5****31	200
31010719-M5****02	800
31010719-M5****56	200
31010719-M5****62	800
31011219-CM****05***9	200
31011519-M5****89	200
310155015-10****86***00	600
310281230-68****05**	200
3103828HH-21****05***56***1	200
311010214-10****69***15	200
311022835-10****71***95	200
311051516-68****12**	200
31120225X-P1****00***HA***BA***N	200
311221611-P1****19***AN***IU***	200
311280043-10****12***51	200
312053016-10****92***51	800
312137844-P1****30***UA***AN***	200
312271219-68****90**	200
312276740-10****77***80	200
312281065-10****79***02	800
312281065-68****90**	200
317118HHH-21****44***04***7	200
3187632HH-21****56***59***5	400
32048319-M3****07	200
32051119-M5****91	200
32052119-M5****70	800
32052119-M5****77	800
32052219-M5****79	200

The followings are the Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) (where supplied) of wholly or partially successful applicants made by giving Electronic Application Instructions to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部份獲接納的申請人的身份證明文件號碼／實益擁有人識別碼(附註)；如有提供，及彼等擁有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼／實益擁有人識別碼(附註)，其結果將不會顯示。

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) 身份證明文件號碼／實益擁有人識別碼(附註)	No. of Shares allotted
--	------------------------

32052219-M5***99	800
32052319-M5***54	200
32058619-M5***13	200
32058619-M5***38	200
32062319-M5***75	200
32062319-M5***86	200
32082319-M5***59	200
32082919-M5***16	200
32091919-M5***02	200
32098119-M5***58	200
32100219-M5***51	200
32118219-M5***84	200
32718109H-21***35***62***9	200
32728038H-21***85***62***6	400
33012119-P3***72	200
33020319-M5***86	200
33020419-M5***46	200
33021119-M5***47	200
33028119-M5***93	200
33030219-M3***09	800
33030219-M3***10	200
33030219-M3***79	800
33030219-M3***82	800
33030219-M3***86	800
33030419-M5***33	200
33030419-M5***41	200
33032519-M5***68	200
33032619-M3***78	800
33032619-M3***82	800
33032719-M3***42	800
33032719-M3***46	800
33032719-M3***55	800
33032719-M3***80	200
33032719-M3***81	800
33032719-M3***86	800
33038219-P3***37	200
33042519-M5***00	200
33072619-M5***26	200
33082219-M3***85	200
33250219-M3***72	800
33313675H-21***33***64***6	200
333177-B0***02***9	200
33526292H-21***31***64***3	200
33900519-M5***69	200
33985813H-21***43***66***1	200
34010319-M5***41	200
34012319-M5***78	200
34082219-M3***98	200
34082819-M5***75	200
34242319-M5***57	200
35012119-M5***08	200
35032119-M5***76	400
350370HHH-21***07***04***5	200
35058319-M3***89	3800
35058319-P3***81	200
35070219-M5***88	200
352807028-35***70***85***F ***E0***00***67	400
356401588-35***15***85***F ***N0***00***95	200
35762650H-21***10***76***3	200
35778532H-21***48***76***7	200
35904999H-21***26***77***6	200
35985888-35***85***85***F ***E0***00***23	400
36010219-M5***07	200
36010219-M5***71	200
36040219-M3***22	200
36073419-M5***26	200
36073519-P3***48	200
361601716-36***17***85***F ***B0***00***70	1600
361304686-36***46***85***F ***N0***00***40	800
36212819-M5***64	200
36222719-M3***51	800
36222719-M5***35	800
36222719-M5***91	800
365891670-36***16***85***F ***E0***00***31	200
36607778H-21***46***78***7	200
36922050H-21***35***79***8	200
37032319-M5***81	200
37063119-M3***08	3800
37132419-M5***80	200
37292619-M5***52	200
37500009H-21***19***68***5	200
37681251H-21***32***81***7	400
37832308H-21***16***68***2	200
38066936H-21***23***81***1	200
38168557H-21***38***81***2	200
38286366H-21***41***82***1	200
38380208H-21***28***83***6	400
38537101H-21***17***82***7	1000
385792486-38***24***85***F ***E0***00***45	400
38708066H-21***40***83***7	200
38721067H-21***94***83***1	200
38768101H-21***28***83***9	200
38896927H-21***14***83***0	400
38919300H-21***29***84***8	200
38922103H-21***92***84***1	200
401292632-P1***82***HO***ON***	200
402177811-P1***04***U ***GJ**	200
405051017-68***76***	200
405223979-10***88***41	2000
406055031-10***95***73	200
406120127-68***19***	200
407107930-10***11***86	200
407152098-10***08***53	3800
408016639-10***87***52	1400
408120023-10***28***65	200
408166886-P1***39***UN***NM**	200
408200447-10***54***72	400
40827692X-P1***40***HA***ZH***NG	200
409273618-10***77***59	200
409280419-P1***17***AO***NG***	200
410030370-10***22***80	1000
41007247X-10***36***66	400
41010219-M5***65	200
41010319-P5***40	200
410184324-10***74***06	200
410210248-60***9***3-*	200
410213919-10***73***09	200
41072519-M5***33	200
41204243X-68***08**	200
41209713X-10***28***12	600
412294526-10***21***59	200
412310011-10***43***78	200
412315313-68***32**	200
42012319-M3***88	200
42022219-M5***89	200
420521198-C0***67**	200
420526197-C0***67**	200
420526198-C0***67**	200
420526199-C0***61**	200
420526199-C0***68**	200
420527197-C0***67**	200
420528197-C0***66**	200
420528197-C0***67**	200
420528197-C0***36**5	200
420528197-C0***36**6	200
420528199-C0***67**	200
42100219-P3***01	200
42108319-M5***79	200

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) 身份證明文件號碼／實益擁有人識別碼(附註)	No. of Shares allotted
--	------------------------

42108719-P3***49	200
42112719-M3***06	200
42112719-M3***61	200
42112719-M3***77	200
42118119-P3***79	200
42220219-M3***30	3800
42220219-M3***92	3800
42230119-M5***71	200
42240319-P3***36	200
422721197-C0***60**	200
422721197-C0***67**	200
422728196-C0***69**	200
426031980-20***71***06***15	200
42900519-P3***56	200
43010319-M5***20	200
43022319-M5***57	200
43062119-M3***40	200
43068219-P3***32	200
43090219-M5***05	200
43092119-M5***78	200
43100219-P3***71	200
43112619-M3***19	200
43123019-P3***09	200
43132219-M5***63	200
43230119-M5***70	200
43250219-M3***58	200
43250319-M3***39	200
43292719-M5***90	200
44010219-M5***14	200
44010419-CM***05***7	1200
44010519-M5***21	200
44010519-M5***81	200
44010619-M5***45	200
44010719-M5***86	200
44010719-P5***99	200
44011119-P3***46	200
440111196-C0***66**	200
44030119-P3***02	200
440301196-C0***63**	200
44030319-M3***81	200
44030419-M5***84	200
44030419-P3***26	200
44030619-M3***12	200
44030719-P3***88	200
440321196-C0***65**	200
44050819-M5***96	200
44052019-M5***71	200
44052819-M3***55	200
44052819-P3***08	200
44052819-P3***19	200
44052819-P3***33	200
44052819-P3***35	200
44052819-P3***73	200
44052819-P3***75	200
44052819-P3***76	200
44058219-M5***97	200
44058219-P3***01	200
44058219-P3***62	200
44068119-M3***53	200
44072119-M5***50	200
44072119-M5***60	200
44072119-M5***69	200
44072119-M5***87	200
44078219-M3***19	200
44078219-M3***20	200
44078219-M3***28	200
44078219-M5***91	200
44078319-M3***10	200
440783199-C0***64**	200
44080419-M3***88	200
44082119-M3***07	200
44082119-P3***04	200
44082119-P3***66	200
44088119-M3***16	200
44088119-M3***61	200
44088219-M5***08	200
44088319-P3***38	200
440924196-C0***64**	200
440924197-C0***60**	200
44098119-M2***39	200
44098219-M3***30	200
44098219-P3***15	200
44122419-P3***23	200
44122419-P3***53	200
44122419-P3***55	200
44122419-P3***85	200
44128319-M3***53	1200
44130119-M5***43	200
44130219-P3***52	200
44130219-P3***62	200
441323196-C0***63**	200
441323197-C0***63**	200
441323198-C0***63**	200
44138119-M5***71	200
44138119-P3***82	200
44142319-P3***02	200
44142319-P3***97	200
44142419-P3***96	200
44142519-M5***82	200
44148119-M3***06	200
44150219-M5***19	200
44152219-P3***63	200
44162119-P3***83	200
441621197-C0***64**	200
44162219-M5***55	200
44162419-P3***69	200
44188219-P3***73	200
44252319-P3***55	200
44520219-P3***45	200
44522119-P3***95	200
44522119-P5***58	800
44522419-M3***52	200
44522419-M3***59	200
44522419-M3***61	200
44522419-M3***71	200
44522419-P3***03	200
44522419-P3***06	200
44522419-P3***25	200
44522419-P3***27	200
44522419-P3***30	200
44522419-P3***57	200
44522419-P3***58	200
44522419-P3***59	200
44522419-P3***61	200
44522419-P3***64	200
44522419-P3***77	200
44522419-P3***80	200
44522419-P3***85	200
44522419-P3***94	200
44522419-P3***96	200
44522419-P3***97	200
44522419-P3***72*	200
44522419-P3***85*	200
44528119-P3***25	200
45010219-P5***39	200
45042319-M5***88	200

The followings are the Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) (where supplied) of wholly or partially successful applicants made by giving Electronic Application Instructions to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部份獲接納的申請人的身份證明文件號碼/實益擁有人識別碼(附註)(如有提供),及彼等擁有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼/實益擁有人識別碼(附註),其結果將不會顯示。

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) 身份證明文件號碼/實益擁有人識別碼(附註)	No. of Shares allotted
45052119-M3***85	200
45052119-P3***17	200
45092119-M5***72	200
45222619-M5***57	200
46000519-P3***26	200
460026197-C0***53**	200
46010319-M5***82	200
50023419-P3***37	200
50038119-M5***38	200
50038319-P3***55	200
501082542-P1***89***U ***IN*	200
50127331X-68***44**	2000
502038671-68***92**	200
502177929-10***93***69	200
502281513-10***40***80	200
503021520-68***84**	600
503118825-10***39***32	200
50314023X-10***00***18	1200
503252837-10***63***10	200
503295767-10***71***21	200
504110018-10***13***51	1600
504111217-68***70**	2400
504230423-P1***20***E ***	200
504270418-10***02***45	400
505035231-68***10**	400
505082228-10***22***59	200
506062414-10***24***5	600
50609001X-68***-8***3-*	3800
507208013-10***24***	200
507221989-20***15***05***58	200
508144831-10***47***15	200
508306840-P1***99***HU***YI**	200
509110501-10***84***13	1000
509227712-68***13**	200
510086648-10***60***38	200
51010319-M5***96	200
51010619-P3***70	200
510108253-10***55***82	400
51011319-M3***21	400
510113945-10***47***80	200
510122010-10***44***47	200
510235766-68***99**	200
510270418-68***94**	200
510272557-68***17**	200
51082319-M5***08	200
511073634-10***10***92	200
511274714-P1***12***HA***AN***G	200
51130219-P3***67	200
51132319-M5***42	200
51132419-P3***16	200
512126838-P1***38***ON***UN**	200
51212851X-68***12**	1200
512192916-10***26***25	200
51292119-P3***97	200
51302219-CM***05***5	200
51370119-M3***39	200
520210319-M3***77	400
52222219-P3***16	200
53292619-M5***14	200
53300119-P3***28	200
563635HHH-21***03***08***7	200
567137HHH-21***12***84***3	200
573630HHH-21***30***08***7	200
590210351-00***44***AN***IN**	200
600407352-00***89***U ***NY**	200
601066845-P1***03***IA***GU***NG	200
60110061X-10***53***91	400
601180510-68***38**	400
601242726-10***19***0	200
602121812-P1***18***AN***NG	200
60216452X-10***72***98	400
604110057-10***15***65	200
604180013-10***23***21	800
605141219-68***74**	200
606110928-P1***89***UA***IN**	200
607112521-P1***99***HA***QI***IA**	200
607180313-10***67***89	800
60719002X-10***73***28	600
607195195-10***83***67	200
609110424-68***07**	200
609267514-10***36***12	200
61010419-P5***47	200
61032419-M5***88	200
61040419-M5***86	800
611030037-10***28***26	200
611224719-P1***15***HE***AO***	200
612264113-10***58***	1600
61232219-M3***55	200
61232219-P3***16	200
62010219-M3***28	200
62232219-M5***40	200
65400119-M5***06	200
6794581-10***77***00***75	200
700318391-00***58***AN***AN*	200
701017518-10***43***01	800
701094729-P1***12***HA***CH***IN	200
701103412-68***31**	200
701152848-10***96***33	200
701294220-10***72***17	200
702086063-68***04**	200
70217122X-10***20***08	200
702232422-10***78***59	200
703211512-10***63***58	200
703253715-10***86***60	200
704054037-10***82***17	200
704062647-10***42***2	800
704063643-10***77***91	200
704172271-68***39**	200
705103123-10***79***60	200
705110637-10***72***63	200
70516891X-10***29***57	200
707100034-68***-7***8-*	200
707270426-10***48***15	200
70812234X-10***97***62	200
708262111-68***68**	200
7010091215-10***13***79	200
710184514-10***05***30	200
710189117-10***54***52	200
711017728-10***61***45	1200
711024112-68***32**	200
711212923-P1***24***HE***IN*	200
711270017-68***31**	200
712111212-10***69***12	2400
759612096-75***20***85***F ***E0***00***15	200
780404481-00***64***EN***HU***N	200
788268084-78***80***85***F ***E0***00***25	14800
800731673-24***82***ON***IN**	200
8011294031-10***28***6	200
801240424-10***24***25	200
802020035-10***28***49	3800
802080039-10***02***91	200
802084334-68***75**	200
802092420-P1***93***IA***LI***	200
802181039-10***17***36	200
803061361-10***56***95	200
803104914-10***52***12	200
803161844-P1***28***HI***UJ*	200
803215014-10***80***63	200

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) 身份證明文件號碼/實益擁有人識別碼(附註)	No. of Shares allotted
803232416-P1***11***AN***ON***AN*	200
803250339-10***71***46	200
804062117-P1***88***EI***JI*	200
804166867-P1***40***HE***UA***G	200
805104818-68***82**	400
805140026-68***23**	200
805246864-P1***98***AN***I	200
806017810-10***85***97	200
806253615-68***21**	400
80703282X-10***65***03	200
807240919-P1***85***EN***IN*	200
808033615-60***-8***4-*	1200
808102221-68***22**	200
808252011-10***26***70	400
809220941-P1***12***EN***UP***	200
810120038-10***23***85	200
810176813-P1***41***ON***EI***	200
810184710-68***28**	400
810203128-10***14***72	200
811095719-10***15***TU***MI*	200
811140419-P1***44***I ***NH**	200
812124749-10***73***00	200
812293053-68***89**	200
820807002-00***37***AN***EI***	200
861108621-00***47***EI***NC**	200
901047812-11***49***G***IA**	3800
901090435-P1***14***I ***NG**	200
901137134-10***80***1	200
901200238-10***28***15	200
901274010-10***71***63	800
902070778-10***03***36*	200
902231429-P1***15***TU***MI*	200
902280045-68***-8***5-*	200
903123511-10***45***20	800
903203335-68***78**	200
903248007-68***32**	400
905210010-68***12**	400
905224224-10***23***06	2000
907071614-10***35***66	200
907251622-10***90***70	200
908123611-10***19***5	2400
90813051X-10***34***69	200
908181777-68***51**	400
908273511-P1***99***HU***YI**	200
909057537-10***62***46	1000
909101614-10***17***1	200
909113526-68***30**	200
909152201-10***60***32	800
910304018-68***-8***6-*	400
911021043-68***08**	200
911032543-10***32***32	200
911104627-68***84**	200
912312515-68***18**	200
912317340-68***31**	200
965630HHH-21***08***13***0	200
A8175052-M2***75	200
A8413536-61***-1***3-*	800
C386572-M2***87	200
C4195254-P1***55***ON***AN***E	200
C5384921-M8***75	3800
C59596833-M6***49	600
C6714440-IB***ON***HA***OF***71***0	400
C6714441-IB***ON***HA***OF***71***1	200
C6714442-IB***ON***HA***OF***71***2	400
C6714443-IB***ON***HA***OF***71***3	400
C6714550-IB***ON***HA***OF***71***0	200
C6714552-IB***ON***HA***OF***71***2	200
C6714555-IB***ON***HA***OF***71***5	200
C6714797-IB***ON***HA***OF***71***7	200
C6714800-IB***ON***HA***OF***71***0	200
C6714801-IB***ON***HA***OF***71***1	200
C6714802-IB***ON***HA***OF***71***2	200
C6714885-IB***ON***HA***OF***71***5	200
C6714887-IB***ON***HA***OF***71***7	200
C6714984-IB***ON***HA***OF***71***4	200
C6715166-IB***ON***HA***OF***71***6	200
C6715181-IB***ON***HA***OF***71***1	200
C6715185-IB***ON***HA***OF***71***5	400
C6715186-IB***ON***HA***OF***71***6	400
C6715212-IB***ON***HA***OF***71***2	200
C6715214-IB***ON***HA***OF***71***4	400
C6715224-IB***ON***HA***OF***71***4	200
C6715231-IB***ON***HA***OF***71***1	200
C6715234-IB***ON***HA***OF***71***4	400
C6715236-IB***ON***HA***OF***71***6	600
C6715244-IB***ON***HA***OF***71***4	200
C6715250-IB***ON***HA***OF***71***0	200
C6715254-IB***ON***HA***OF***71***4	200
C6715265-IB***ON***HA***OF***71***5	800
C6715303-IB***ON***HA***OF***71***3	200
D0702553	3800
D2475651-61***-1***7-*	400
D5188041-A9***66	200
D5711402-M2***22	200
D8126098-21***62*	3800
E32395340-SH***U***G	2800
E6867077-M2***56	200
E789386-NC***H ***	400
E82291584-88***80***I ***G	200
E956878-M7***51	200
E9203269-P7***79	30000
E9459794-M2***97	200
G099282-CH***KI***SA**	2400
G2598514-M5***63	200
G4276220-60***-9***7-*	2000
G4549014-M9***06	200
G6053164	800
G6538745-A5***85***8	600
G7012526-M2***80	200
G8093759-M8***80	200
G8217849-M8***48	3800
GS057252B-GA***IN*	200
GS072167B-WA***CH***AN	400
GS123925B-CH***DA*	800
GS133091B-WA***ZH***NG	200
GS158623B-BZ***U	3800
GS188790B-YA***SH***YU	2400
H3777822-M8***0	800
I869490-IB***ON***HA***OF***69***	3800
I869494-IB***ON***HA***OF***69***	200
I869519-IB***ON***HA***OF***69***	200
I869525-IB***ON***HA***OF***69***	200
I869526-IB***ON***HA***OF***69***	200
I869527-IB***ON***HA***OF***69***	2000
I869528-IB***ON***HA***OF***69***	200
K0971537-8F***8B***FD***1E***U ***MO***PU	1200
K1322389-M2***53	3800
K1418130-62***-1***3-*	200
K2162946-M5***61	200
K297049A	800
K3010724-P9***	200
K3155102-M8***87	200
K4806107-M7***88	200
K5295807-64***-1***7-*	200
K7174802-A3***39	200
K7593848-P7***95	200
K9215506-P8***21	3800
K927362A-P8***61	3800

Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS

The followings are the Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) (where supplied) of wholly or partially successful applicants made by giving Electronic Application Instructions to HKSCC via CCASS and the number of Hong Kong Offer Shares conditionally allotted to them. Applicants who have not provided their Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) are not shown.

透過中央結算系統向香港結算發出電子認購指示申請的配發結果

以下為透過中央結算系統向香港結算發出電子認購指示申請而全部或部份獲接納的申請人的身份證明文件號碼/實益擁有人識別碼(附註)(如有提供)及彼等獲有條件配發的香港發售股份數目。如申請人未有提供身份證明文件號碼/實益擁有人識別碼(附註),其結果將不會顯示。

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note)	No. of Shares allotted
身份證明文件號碼/實益擁有人識別碼(附註)	獲配發股份數目
K9370471-A6***43	200
M0263589-P7***46	200
M1097569-P1***55***UA***YU***AN*	200
M6309920-M5***86	200
M7337588-A3***62	800
M7339718-A5***63	800
OS136945-10***69***13***5	400
OS167841-10***78***16***1	200
OS919054-10***90***91***4	200
P0241753-M8***20	3800
P0351931-P8***88	200
P0650637-M5***06	3800
P594079-CM***05***8	800
P6005261-M8***33	3800
P6410018-A5***47	200
P642521A-M5***41	200
P6617585-M9***16	800
P7248060-68***-8***4-*	800
P7465053-P8***95	1200
P8069089-M7***33	200
P9530618-M5***4	3800
R1639101-P1***55***IA***IN***ON*	200
R1777407-68***98**	400
R3870587-M4***00	200
R4013335-M9***91	200
R4904841-62***-8***1-*	200

Identification document number(s) / Beneficiary Owner Identification Code(s) (Note)	No. of Shares allotted
身份證明文件號碼/實益擁有人識別碼(附註)	獲配發股份數目
R6025292-M6***63	3800
R8398649	800
S8579072B-10***02***39*	1000
V0310042-M8***9	3800
V1148273-M5***9	3800
V1148281-M5***3	3800
Y023249A-P7***21	200
Y0375010-M4***53	2000
Y2047347-M5***05	3800
Y2484259-21***84*	200
Y4411933-M2***81	3800
Y523248A-A8***25	200
Z0705447-21***87*	800
Z097569A-38***8	200
Z1833813-M7***46	200
Z2346150-P7***41	200
Z2576547-M5***2	3800
Z2677092-M2***80	3800
Z3512240-M8***6	3800
Z3615880-M8***38	3800
Z474823A-M8***71	3800
Z6234683-M5***8	3800
Z8168467-B0***95***3A***E0***N *** S***HA	200
Z830089-HO***NG***UN	200
Z9297481-P8***49	3800

Note: Beneficiary Owner Identification Code(s) are codes provided by nominees as an agent making the application for the benefit of another person in WHITE Applications Form or brokers via CCASS.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed "Results of Applications Made by WHITE Applications Forms or White Form eIPO" and "Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS" are redacted and not all details of applications are disclosed in this announcement.

The list of identification document number(s) in this announcement is not a complete list of successful applicants since only successful applicants whose identification document numbers are provided by CCASS are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated above. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result.

Identification document numbers shown in the sections headed "Results of Applications Made by WHITE Applications Forms or White Form eIPO", "Results of Applications Made by BLUE Application Forms" and "Results of Applications Made by YELLOW Application Forms (Through Designated CCASS Clearing/Custodian Participants)" refer to Hong Kong identity card numbers / passport numbers /Hong Kong business registration numbers/ beneficial owner identification codes provided by nominees as an agent making the application for the benefit of another person whereas those displayed in the section headed "Results of Applications Made by Giving Electronic Application Instructions to HKSCC via CCASS" are provided by brokers via CCASS. Therefore, some of the identification document numbers shown in these sections are different in nature.

附註：實益擁有人識別碼乃由經紀透過中央結算系統或由代理為其他人士利益於白色申請表格內提出申請所提供的識別碼。

由於申請須遵守個人資料收集聲明，「以白色申請表格或白表eIPO提出申請的配發結果」及「透過中央結算系統向香港結算發出電子認購指示提出申請的配發結果」等節所示的實益擁有人識別碼乃予以編纂，且並未於本公告中披露所有申請詳情。

由於僅披露由中央結算系統提供其身份證明文件號碼的獲接納申請人，故本公告中的身份證明文件號碼清單並非獲接納申請人的完整清單。僅擁有實益姓名但無身份證明文件號碼的申請人因下文所述的個人私隱而不予披露。透過彼等經紀申請認購發售股份的申請人可諮詢經紀查詢彼等的申請結果。

「以白色申請表格或白表eIPO提出申請的配發結果」、「以藍色申請表格提出申請的配發結果」及「以黃色申請表格提出申請的配發結果（透過指定中央結算系統結算／託管商參與者）」等節所示的身份證明文件號碼指香港身份證號碼、護照號碼、香港商業登記號碼、由代理為其他人士利益提出申請所提供的實益擁有人識別碼，而「透過中央結算系統向香港結算發出電子認購指示提出申請的配發結果」一節所示的該等號碼乃由經紀透過中央結算系統提供。因此，該等節所示的個別身份證明文件號碼在本質上有所不同。

Results of Applications Made by BLUE Application Form

The followings are the Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) (where supplied) of wholly or partially successful applicants using BLUE Application Form and the number of Reserved Shares conditionally allotted to them. Applicants who have not provided their Identification document number(s) / Beneficiary Owner Identification Code(s) (Note) are not shown.

以藍色申請表格提出申請的配發結果

以下為使用藍色申請表格提出申請而全部或部份獲接納的申請人的身份證明文件號碼/實益擁有人識別碼(附註)(如有提供)及彼等獲有條件配發的預留股份數目。如申請人未有提供身份證明文件號碼/實益擁有人識別碼(附註),其結果將不會顯示。

Identification Document Number(s) (Note) 證件號碼(附註)	HKPO Shares Allocated 獲配發股份
K1273760	5
K6656579	5
K6656579	5

Identification Document Number(s) (Note) 證件號碼(附註)	HKPO Shares Allocated 獲配發股份
K6656579	5
Z7707917	3

DESPATCH/COLLECTION OF H SHARE CERTIFICATES/e-REFUND PAYMENT INSTRUCTIONS/REFUND CHEQUE(S)

Applicants who applied for (i) 100,000 or more Hong Kong Offer Shares through **White Form eIPO** service; or (ii) **BLUE** Application Form for 100,000 or more Reserved Shares under Preferential Offering and have provided all information required by the Application Form may collect any refund cheque (where applicable) and/or H Share certificates in person from our H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong from 9:00 a.m. to 1:00 p.m. on Thursday, December 29, 2022 or such other date as notified by us as the date of dispatch/collection of H Share certificates/e-Refund payment instructions/refund cheque.

Applicants being individuals who are eligible for personal collection cannot authorize any other person to make collection on their behalf. Corporate applicants which are eligible for personal collection must attend by their authorized representatives bearing letters of authorization from their corporations stamped with the corporations' chops. Both individuals and authorized representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Computershare Hong Kong Investor Services Limited.

H Share certificates for Hong Kong Offer Shares allotted to applicants who applied for less than 100,000 Hong Kong Offer Shares through the **White Form eIPO** are expected to be despatched to those entitled to the addresses specified in the relevant application instructions by ordinary post at their own risk on or before Thursday, December 29, 2022.

H Share certificates and/or refund cheque(s) for Hong Kong Offer Shares allocated to applicants who applied through the **White Form eIPO** service which are either not available for personal collection or which are available but are not collected in person by 1:00 p.m. on Thursday, December 29, 2022 are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on or before Thursday, December 29, 2022.

Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their H Share certificates issued in the name of HKSCC Nominees Limited and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave **electronic application instructions** on their behalf on Thursday, December 29, 2022.

Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies payable to them with that CCASS Participant.

Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS should check and report any discrepancies to HKSCC before 5:00 p.m. on Thursday, December 29, 2022 or such other date as shall be determined by HKSCC or HKSCC Nominees. Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS may also check the results of their applications and the amount of refund monies payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An

Operating Guide for Investor Participants” in effect from time to time). Immediately following the credit of the Hong Kong Offer Shares to the CCASS Investor Participants stock accounts and the credit of the refund monies to their respective designated bank account (if any), HKSCC will also make available to the CCASS Investor Participants an activity statement showing the number of the Hong Kong Offer Shares credited to their stock accounts and the amount of refund monies (if any) credited to their respective designated bank accounts.

Applicants who applied through the **White Form eIPO** service and paid the application monies from a single bank account may have refund monies (if any) despatched to their application payment account in the form of e-Refund payment instructions on Thursday, December 29, 2022. Applicants who applied through the **White Form eIPO** service and paid the application monies from multiple bank accounts will have refund monies (if any) despatched to the addresses specified on their **White Form eIPO** applications in the form of refund cheque(s) in favour of the applicant (or, in case of joint applications, the first-named applicant), by ordinary post at their own risk on or before Thursday, December 29, 2022.

Refund monies for applicants who have applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to their designated bank accounts or the designated bank accounts of their **brokers** or **custodians** on Thursday, December 29, 2022.

H Share certificates will only become valid at 8:00 a.m. (Hong Kong time) on Friday, December 30, 2022 provided that the Global Offering has become unconditional in all respects at or before that time and neither of the Hong Kong Underwriting Agreement nor the International Purchase Agreement is terminated in accordance with its respective terms prior to 8:00 a.m. on Friday, December 30, 2022.

The Company will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

PUBLIC FLOAT

The Company confirms that immediately after the completion of the Global Offering, 92,400,182 H Shares, representing approximately 18.14% of the total issued Shares upon completion of the Global Offering (assuming the Over-allotment Option is not exercised) will count towards the public float for the purpose of Rule 8.08 of the Listing Rules.

The Company has applied to the Stock Exchange to request the Stock Exchange to exercise its discretion under Rule 8.08(1)(d) of the Listing Rules, and the Stock Exchange has granted a waiver from strict compliance with the requirements of Rule 8.08(1)(a) of the Listing Rules, pursuant to which the public float of the Company may fall below 25% of the issued share capital (assuming the Over-allotment Option is not exercised) or such higher percentage of H Shares held by the public (if the Over-allotment Option is fully or partially exercised).

The Directors confirm that (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company immediately after the Global Offering; (iii) the number of Shares in public hands will satisfy the minimum percentage as approved by the Hong Kong Stock Exchange; (iv) the three largest

public Shareholders of the Company do not hold more than 50% of the Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (v) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

Immediately following completion of the Global Offering and before the exercise of the Over-allotment Option, (i) the number of H Shares in public hands will be 92,400,182 H Shares, representing 18.14% of the total issued share capital of the Company which satisfies the minimum percentage prescribed in the conditions imposed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1) of the Listing Rules; and (ii) the Company will comply with Rule 18A.07 of the Listing Rules that a portion of the total number of the Company's issued shares with a market capitalization of at least HK\$375 million will be held by the public at the time of Listing.

COMMENCEMENT OF DEALINGS

Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. (Hong Kong time) on Friday, December 30, 2022, dealings in the H Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. (Hong Kong time) on Friday, December 30, 2022. H Shares will be traded in board lots of 200 H Shares each. The stock code of the H Shares is 6955.

By order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
*Chairlady, Chief Executive Officer and
Executive Director*

Hong Kong, December 29, 2022

Directors of the Company named in the application to which this announcement relates are: (i) Ms. Jiang Hua and Dr. Dou Changlin as executive Directors; (ii) Dr. Li Youxin, Mr. Liu Yuanchong, Ms. Li Li and Mr. Chen Jie as non-executive Directors; and (iii) Mr. Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin as independent non-executive Directors.